Authors
Loading...
Systemic delivery barriers persist in DM1 therapy development; leaves open optimization of targeted compounds before clinical translation.
Key points are not available for this paper at this time.
González‐Barriga et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: